Scott G. Lamont

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Amine-Promoted, Organocatalytic Aziridination of Enones

Alan Armstrong, Carl A. Baxter, Scott G. Lamont et al. · Organic Letters · 2006 · 112 citations

Pharmacy, Medicinal Chemistry, Organometallic Chemistry +9

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3

Scott Boyd, Joanna Brookfield, Susan E. Critchlow et al. · Journal of Medicinal Chemistry · 2015 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3<i>R</i>)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)

Robert H. Bradbury, Rowena Callis, Gregory R. Carr et al. · Journal of Medicinal Chemistry · 2016 · 86 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15